Diabetes and Cardiovascular Disease, SGLT2 inhibitors and GLP1 receptor agonists with Dr. Peter Toth
05/04/23 • 45 min
We would love to hear your thoughts on the episodes!
Dr. Thomas Nero speaks with Dr Peter Toth about the dramatic change occuring in diabtetes management and its effect on cardiovascular disease. Starting with the biochemestry of diabetes and its effects at the cellular level, the discussion goes on to speak about the role SGLT2 inhibitors and GLP1 receptor agonists play in DM management as well as the future of diabetes care. (If you want to skip the excelllent, but quite deep dive into biochemistry, jump to 11:22 - but honestly Dr. Toth's description is breathtaking)
We would love to hear your thoughts on the episodes!
Dr. Thomas Nero speaks with Dr Peter Toth about the dramatic change occuring in diabtetes management and its effect on cardiovascular disease. Starting with the biochemestry of diabetes and its effects at the cellular level, the discussion goes on to speak about the role SGLT2 inhibitors and GLP1 receptor agonists play in DM management as well as the future of diabetes care. (If you want to skip the excelllent, but quite deep dive into biochemistry, jump to 11:22 - but honestly Dr. Toth's description is breathtaking)
Previous Episode
Lipids, Lipid Sub-fractionations and Inflammation, Putting It All Together with Dr Peter Toth
We would love to hear your thoughts on the episodes!
Dr. Thomas Nero speaks with Dr. Peter Toth about the complex biology of lipids and atherosclerosis. In this episode Dr Toth dives into LDL goals, therapies for attenuating non-LDL risk, vascular biology and the where are research studies lead us in choosing therapies.
Next Episode
Anticoagulation, Thombin Generation and Factor XI inhibition in ACS and Atrial Fibrillation with Dr C. Michael Gibson
We would love to hear your thoughts on the episodes!
Dr. Thomas Nero discusses current therapy with Factor X inhibitors, the new research with Factor XI inhibition and specifically the enrolling Milvexian clinical trials with Dr. C Micahel Gibson. In addition they discuss, the addition of these medications along wiht anti-platelet therapy, Lp(a) and other interesting current and future research in cardiovascular disease.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/future-pulse-cardiology-277889/diabetes-and-cardiovascular-disease-sglt2-inhibitors-and-glp1-receptor-34302554"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to diabetes and cardiovascular disease, sglt2 inhibitors and glp1 receptor agonists with dr. peter toth on goodpods" style="width: 225px" /> </a>
Copy